Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), ...

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

We recently published a list of the 10 Worst Performing Stocks in S&P 500 in 2024. In this article, we are going to take a ...

Pharmaceutical company Moderna (MRNA) has seen its stock slump in recent months. The share price peaked at $150 in early ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we ...

Shares of Moderna Inc. MRNA slid 2.95% to $50.28 Thursday, on what proved to be an all-around mixed trading session for the ...

In the latest market close, Moderna (MRNA) reached $54.36, with a -0.66% movement compared to the previous day. The stock's performance was ahead of the S&P 500's daily loss of 1.86%. Meanwhile, the ...

Detailed price information for Moderna Inc (MRNA-Q) from The Globe and Mail including charting and trades.

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global ...

Current Moderna shareholders who have held Moderna shares since on or before January 18, 2023, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a ...